Opportunity Information: Apply for W81XWH 21 PRORP CTA
The DoD Peer Reviewed Orthopaedic Research Program (PRORP) Clinical Trial Award (CTA) is a Department of Defense funding opportunity meant to move orthopaedic solutions into real-world patient testing quickly. Its purpose is to support the rapid start and execution of human clinical trials that could materially improve the treatment or management of orthopaedic injuries affecting Service members and Veterans, especially combat-related injuries and non-battle injuries that still significantly reduce unit readiness and delay return to duty or work. A central theme of the award is practicality and near-term impact: applicants are pushed to explain how their trial could help deliver effective care closer to the point of injury and/or shorten the timeline for functional recovery and return to duty/work.
This mechanism is strictly limited to clinical trials in human subjects, not animal work, not bench studies, and not general clinical research that does not prospectively assign participants to an intervention. In this announcement, a clinical trial is defined in the standard federal way: a research study where one or more human subjects are prospectively assigned to one or more interventions (including placebo or other controls) to evaluate effects on biomedical or behavioral health-related outcomes. The program explicitly contrasts the CTA with the PRORP Clinical Translational Research Award (CTRA): the CTRA can support broader clinical research, while the CTA is only for studies that meet the clinical trial definition. Projects can range from smaller, early stage trials (pilot studies, first-in-human efforts, phase 0 style feasibility trials) up through larger trials designed to determine efficacy in relevant patient populations. The types of interventions the DoD is willing to support are broad as long as they are trial-ready, including new products, drugs or biologics, medical devices, clinical guidance, and emerging approaches or technologies.
Funding is structured around Research Levels. All applications, regardless of focus area, are eligible for Research Level 1. A specific enhanced pathway, the Rehabilitation Option (Research Level 2), is available only for applications within the "Translation of Early Findings - Soft Tissue Trauma" focus area. This option is meant to incentivize truly integrated interdisciplinary work between surgical/trauma clinicians and rehabilitation professionals. Under this model, the project must combine surgical strategies (for example, reconstruction and repair and/or the use of biologics, pharmaceuticals, or devices aimed at restoring tissue architecture and function) with rehabilitative strategies (approaches intended to restore function and independence after injury). The expectation is that the integration creates added value beyond what surgery or rehab would accomplish in isolation. Applicants must spell out the rehabilitation strategy and the relevant standard of care, and trials that follow patients across the continuum of care are encouraged. To ensure the collaboration is real, the team must include at least one investigator with orthopaedic rehabilitation expertise and at least one clinician specializing in orthopaedic or trauma care, and letters of collaboration from both are required for this option.
Because the program is designed to test interventions in humans, it places strong emphasis on regulatory readiness and compliance. If a proposed trial uses a drug that is not FDA-approved for the intended investigational use, an Investigational New Drug (IND) application under 21 CFR 312 may be required. If a device is being studied, an Investigational Device Exemption (IDE) under 21 CFR 812 may be required (or the device may qualify for an abbreviated IDE). In either case, it is on the applicant to provide documentation from the Institutional Review Board (IRB) of record or from the FDA indicating whether an IND/IDE is or is not required. When an IND or IDE is required, it must be submitted to the FDA within 6 months of the award date, and it must match the specific product/device and the indication being tested (meaning the submission cannot be for a different derivative or modified version than what the trial will actually use). If international sites are involved for investigational products, the relevant host-country regulatory applications must also be filed within 6 months. The government explicitly reserves the right to withdraw funding if required regulatory submissions are not made on time, underscoring that this award is intended for trials that are operationally ready to launch.
The announcement lays out a detailed picture of what a competitive, fundable trial should look like. Preliminary data relevant to the proposed clinical trial is required, and the trial is expected to begin within 12 months after the award date, reinforcing the "rapid implementation" goal. The intervention being tested needs to have credible potential for significant impact on military and Veteran outcomes related to orthopaedic injuries and readiness. The trial must be grounded in a sound scientific rationale supported by careful reasoning and a critical review of existing literature, rather than speculative claims. Practical feasibility is treated as essential: applicants must show access to a suitable patient population, explain how accrual goals will be met, and discuss how standards of care could influence enrollment or outcomes. They must also document access to the drug/device/materials for the duration of the study and address product quality and stability in a way that matches applicable FDA manufacturing expectations (such as GMP and Quality System Regulation standards depending on product type and development phase).
Operational trial rigor is another major emphasis. Applications are expected to present clear objectives and appropriate endpoints or outcome measures, and trials must comply with Good Clinical Practice (GCP). A solid statistical foundation is required, including an explicit statistical analysis plan, appropriate statistical expertise on the team, and a power analysis that justifies sample size projections and demonstrates the study can answer its primary questions. Applicants must also provide a data management plan and use an appropriate database to protect data integrity; if the trial is FDA-regulated, a 21 CFR Part 11-compliant database and appropriate data standards are required. In addition, the program expects a safety management plan (including pharmacovigilance when applicable), and a clinical monitoring plan that explains how the study will be monitored for GCP compliance. The announcement also calls out the importance of having study coordinator support to shepherd the protocol through local IRB and other regulatory processes, coordinate across multiple sites if needed, and manage participant recruitment.
The DoD also cares about what happens after the trial ends, not just whether it gets published. Applications must include a Transition Plan describing how the product or approach will move to the next clinical trial phase and/or toward market delivery after successful completion. Strong institutional support or an industry partnership is viewed as important, and when applicable the application should show a commitment to serve as the FDA regulatory sponsor and fulfill sponsor responsibilities (notably those described for drugs in 21 CFR 312, Subpart D). On the transparency and public accountability side, funded trials must register on ClinicalTrials.gov prior to initiating the study, and they are required to post the IRB-approved informed consent form on a publicly available federal website in accordance with federal requirements referenced in 32 CFR 219.
Mechanically, awards under this announcement are issued as assistance agreements, meaning the government is supporting a public purpose rather than purchasing a deliverable for direct government use. Depending on the expected level of DoD involvement during performance, the award may be a grant (when no substantial involvement is anticipated, consistent with 31 USC 6304) or a cooperative agreement (when substantial involvement is anticipated, consistent with 31 USC 6305). The final choice between grant and cooperative agreement, along with the project start date, is determined during negotiations, and cooperative agreements will spell out the nature of the government involvement (such as collaboration or participation in aspects of the effort).
Budget and scale are clearly bounded. Total costs for the entire period of performance are capped at $2.25 million for Research Level 1 and $2.75 million for Research Level 2. For FY21, the program anticipated allocating roughly $9 million to fund about four Research Level 1 awards and about $5.5 million to fund two Research Level 2 awards, for a total expectation of six awards. Eligibility is described as unrestricted (open to any type of entity, subject to any clarifications in the full announcement). Key administrative details in the source listing include the opportunity number W81XWH-21-PRORP-CTA, administering agency listed as the Department of Defense / Department of the Army (USAMRAA), a creation date of April 1, 2021, an original closing date of September 10, 2021, and an intent that awards be made no later than September 30, 2022. Like many DoD opportunities, actual funding depends on federal fund availability and on scientific and programmatic review outcomes. The funds anticipated for awards are FY21 funds with a use expiration of September 30, 2027, which matters for project planning and the timing of expenditures.
Overall, the PRORP Clinical Trial Award is best understood as a trial-startup-and-execution mechanism aimed at high-impact, near-term orthopaedic solutions for warfighter and Veteran needs. It prioritizes readiness and return-to-function outcomes, demands convincing preliminary evidence and a strong operational plan, and expects applicants to be prepared for real regulatory, data, safety, and monitoring obligations typical of FDA-relevant clinical trials.Apply for W81XWH 21 PRORP CTA
- The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Peer Reviewed Orthopaedic, Clinical Trial Award" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
- This funding opportunity was created on Apr 01, 2021.
- Applicants must submit their applications by Sep 10, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 6 candidate(s).
- Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
PRORP Clinical Trial Award (CTA) - FAQs
What is the PRORP Clinical Trial Award (CTA)?
The DoD Peer Reviewed Orthopaedic Research Program (PRORP) Clinical Trial Award (CTA) is a Department of Defense funding opportunity designed to rapidly start and execute clinical trials in human subjects. It is intended to move orthopaedic solutions into real-world patient testing quickly, with an emphasis on near-term, practical impact for Service members and Veterans.
What is the main purpose of this award?
The purpose is to support human clinical trials that could materially improve the treatment or management of orthopaedic injuries affecting Service members and Veterans. The program emphasizes outcomes that improve unit readiness and help shorten the timeline for functional recovery and return to duty or return to work.
What kinds of injuries or needs is the DoD prioritizing?
The CTA prioritizes orthopaedic injuries affecting Service members and Veterans, including combat-related injuries and non-battle injuries that significantly reduce unit readiness and delay return to duty or work.
Is this opportunity only for clinical trials in humans?
Yes. This mechanism is strictly limited to clinical trials in human subjects. It is not intended for animal studies, bench/lab studies, or general clinical research that does not meet the federal definition of a clinical trial.
How does this announcement define a "clinical trial"?
A clinical trial is defined using the standard federal definition: a research study in which one or more human subjects are prospectively assigned to one or more interventions (which can include placebo or other controls) to evaluate the effects on biomedical or behavioral health-related outcomes.
What types of projects are not a fit for this CTA mechanism?
Projects that are not prospective interventional clinical trials in human subjects are not a fit. The announcement explicitly indicates that animal work, bench studies, and clinical research that does not prospectively assign participants to an intervention fall outside the scope of this award.
How is the CTA different from the PRORP Clinical Translational Research Award (CTRA)?
The CTA is limited to studies that meet the federal clinical trial definition. The PRORP Clinical Translational Research Award (CTRA) can support broader clinical research, but the CTA is only for clinical trials.
What stages of clinical trials can be supported?
The CTA can support a range of clinical trial stages, from smaller early-stage trials (such as pilot studies, first-in-human efforts, or phase 0-style feasibility trials) through larger trials designed to determine efficacy in relevant patient populations.
What kinds of interventions can be tested under this award?
The program is open to a broad range of trial-ready interventions, including new products, drugs or biologics, medical devices, clinical guidance, and emerging approaches or technologies, as long as they are suitable for testing in a human clinical trial.
What is the "central theme" of the CTA?
A central theme is practicality and near-term impact. Applicants are expected to explain how their trial could help deliver effective care closer to the point of injury and/or shorten the timeline for functional recovery and return to duty/work.
What are the Research Levels for this opportunity?
Funding is structured around Research Levels. All applications are eligible for Research Level 1. A specific enhanced pathway, the Rehabilitation Option (Research Level 2), is available only for applications within the "Translation of Early Findings - Soft Tissue Trauma" focus area.
What is Research Level 2 (Rehabilitation Option), and who can apply for it?
Research Level 2 is a Rehabilitation Option intended to incentivize truly integrated interdisciplinary work between surgical/trauma clinicians and rehabilitation professionals. It is only available to applications within the "Translation of Early Findings - Soft Tissue Trauma" focus area.
What does "integrated" mean for the Rehabilitation Option?
For Research Level 2, the project must combine surgical strategies (such as reconstruction and repair and/or the use of biologics, pharmaceuticals, or devices aimed at restoring tissue architecture and function) with rehabilitative strategies (approaches intended to restore function and independence after injury). The application is expected to show that the integration adds value beyond what surgery or rehabilitation would accomplish alone.
Are there team requirements for the Rehabilitation Option (Research Level 2)?
Yes. The team must include at least one investigator with orthopaedic rehabilitation expertise and at least one clinician specializing in orthopaedic or trauma care. Letters of collaboration from both are required for this option.
Does the CTA require preliminary data?
Yes. Preliminary data relevant to the proposed clinical trial is required.
How quickly does the DoD expect trials to start after award?
The trial is expected to begin within 12 months after the award date, consistent with the program goal of rapid implementation.
What regulatory requirements are emphasized in this opportunity?
The CTA places strong emphasis on regulatory readiness and compliance. Depending on the intervention, an Investigational New Drug (IND) application (21 CFR 312) or an Investigational Device Exemption (IDE) application (21 CFR 812) may be required. Applicants must also address IRB expectations and compliance with Good Clinical Practice (GCP).
When might an IND be required?
If the proposed trial uses a drug that is not FDA-approved for the intended investigational use, an IND under 21 CFR 312 may be required.
When might an IDE be required?
If a device is being studied, an IDE under 21 CFR 812 may be required, or the device may qualify for an abbreviated IDE.
What documentation is required regarding IND/IDE status?
Applicants must provide documentation from the IRB of record or from the FDA indicating whether an IND/IDE is or is not required.
If an IND or IDE is required, what is the timeline for submission?
When an IND or IDE is required, it must be submitted to the FDA within 6 months of the award date.
Does the IND/IDE submission need to match the exact intervention being tested?
Yes. The IND or IDE must match the specific product/device and the indication being tested. The submission cannot be for a different derivative or modified version than what the trial will actually use.
What if the trial includes international sites and investigational products?
If international sites are involved for investigational products, the relevant host-country regulatory applications must also be filed within 6 months.
Can funding be withdrawn for missing regulatory deadlines?
Yes. The government explicitly reserves the right to withdraw funding if required regulatory submissions are not made on time.
What does the DoD expect regarding feasibility and participant accrual?
Applicants are expected to demonstrate access to a suitable patient population, explain how accrual goals will be met, and discuss how standards of care could influence enrollment or outcomes.
Do applicants need to show access to the intervention or materials?
Yes. Applicants must document access to the drug/device/materials for the duration of the study.
Are product quality and stability considerations part of the application expectations?
Yes. Applicants are expected to address product quality and stability consistent with applicable FDA manufacturing expectations, such as GMP and Quality System Regulation standards depending on product type and development phase.
What does the program expect for trial design and endpoints?
Applications are expected to present clear objectives and appropriate endpoints or outcome measures, and trials must comply with Good Clinical Practice (GCP).
What statistical elements are expected in a competitive application?
The announcement emphasizes a solid statistical foundation, including an explicit statistical analysis plan, appropriate statistical expertise on the team, and a power analysis to justify sample size projections and show the study can answer its primary questions.
What are the data management expectations?
Applicants must provide a data management plan and use an appropriate database to protect data integrity. If the trial is FDA-regulated, a 21 CFR Part 11-compliant database and appropriate data standards are required.
What safety oversight does the CTA expect?
The program expects a safety management plan, including pharmacovigilance when applicable.
What monitoring expectations are included?
The CTA expects a clinical monitoring plan that explains how the study will be monitored for Good Clinical Practice (GCP) compliance.
Is study coordinator support discussed in the announcement?
Yes. The announcement highlights the importance of study coordinator support to guide protocols through IRB and regulatory processes, coordinate across multiple sites when needed, and manage participant recruitment.
What is a Transition Plan, and is it required?
A Transition Plan is required and should describe how the product or approach will move to the next clinical trial phase and/or toward market delivery after successful completion of the funded trial.
Does the DoD value industry partnerships or institutional support?
Yes. Strong institutional support or an industry partnership is viewed as important for transition beyond the funded effort.
Is there an expectation related to FDA sponsor responsibilities?
When applicable, the application should show a commitment to serve as the FDA regulatory sponsor and fulfill sponsor responsibilities, including those described for drugs in 21 CFR 312, Subpart D.
Are funded trials required to register on ClinicalTrials.gov?
Yes. Funded trials must register on ClinicalTrials.gov prior to initiating the study.
Are there informed consent posting requirements?
Yes. Funded trials are required to post the IRB-approved informed consent form on a publicly available federal website, consistent with federal requirements referenced in 32 CFR 219.
What type of award instrument will be used (grant vs cooperative agreement)?
Awards are issued as assistance agreements. Depending on the expected level of DoD involvement, the award may be a grant (when no substantial involvement is anticipated, consistent with 31 USC 6304) or a cooperative agreement (when substantial involvement is anticipated, consistent with 31 USC 6305).
Who decides whether the award is a grant or a cooperative agreement?
The final choice between a grant and a cooperative agreement is determined during negotiations. For cooperative agreements, the nature of government involvement (such as collaboration or participation in aspects of the effort) will be described.
What are the budget caps for this opportunity?
Total costs for the entire period of performance are capped at $2.25 million for Research Level 1 and $2.75 million for Research Level 2.
How many awards were anticipated for FY21?
For FY21, the program anticipated allocating roughly $9 million to fund about four Research Level 1 awards and about $5.5 million to fund two Research Level 2 awards, for a total expectation of six awards.
Who is eligible to apply?
Eligibility is described as unrestricted, meaning it is open to any type of entity, subject to any clarifications in the full announcement.
What is the opportunity number and administering agency?
The opportunity number is W81XWH-21-PRORP-CTA. The administering agency is listed as the Department of Defense / Department of the Army (USAMRAA).
What were the listed dates for creation, closing, and expected award timing?
The source listing includes a creation date of April 1, 2021, an original closing date of September 10, 2021, and an intent that awards be made no later than September 30, 2022.
Is funding guaranteed if an application is submitted?
No. Like many DoD opportunities, actual funding depends on federal fund availability and on scientific and programmatic review outcomes.
What does it mean that the funds are FY21 funds with a use expiration of September 30, 2027?
The announcement notes that anticipated award funds are FY21 funds with a use expiration of September 30, 2027, which can matter for project planning and the timing of expenditures.
Browse more opportunities from the same category: Science and Technology and other Research and Development
Next opportunity: Fiscal Year (FY) 2021 Emergency Management Baseline Assessment Grant (EMBAG)
Previous opportunity: INDO-PACIFIC SCHOLAR CONNECT
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for W81XWH 21 PRORP CTA
Applicants also applied for:
Applicants who have applied for this opportunity (W81XWH 21 PRORP CTA) also looked into and applied for these:
| Funding Opportunity |
|---|
| DoD Peer Reviewed Orthopaedic, Applied Research Award Apply for W81XWH 21 PRORP ARA Funding Number: W81XWH 21 PRORP ARA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOD Orthotics and Prosthetics Outcomes, Clinical Trial Award Apply for W81XWH 21 OPORP CTA Funding Number: W81XWH 21 OPORP CTA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOD Orthotics and Prosthetics Outcomes, Clinical Research Award Apply for W81XWH 21 OPORP CRA Funding Number: W81XWH 21 OPORP CRA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer, Early Investigator Research Award Apply for W81XWH 21 PCRP EIRA Funding Number: W81XWH 21 PCRP EIRA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer, Health Disparity Research Award Apply for W81XWH 21 PCRP HDRA Funding Number: W81XWH 21 PCRP HDRA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer, Idea Development Award Apply for W81XWH 21 PCRP IDA Funding Number: W81XWH 21 PCRP IDA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer, Translational Science Award Apply for W81XWH 21 PCRP TSA Funding Number: W81XWH 21 PCRP TSA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer, Physician Research Award Apply for W81XWH 21 PCRP PRA Funding Number: W81XWH 21 PCRP PRA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| CDDRR Capacity Development for Weather, Water, and Climate Forecasting and Disaster Risk Reduction Apply for NOAA NWS NWSPO 2021 2006845 Funding Number: NOAA NWS NWSPO 2021 2006845 Agency: Department of Commerce Category: Science and Technology and other Research and Development Funding Amount: $15,000,000 |
| DoD Prostate Cancer, Data Science Award Apply for W81XWH 21 PCRP DSA Funding Number: W81XWH 21 PCRP DSA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer, Clinical Consortium Award Apply for W81XWH 21 PCRP CCA Funding Number: W81XWH 21 PCRP CCA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer, Health Equity Research and Outcomes Improvement Consortium Award Apply for W81XWH 21 PCRP HEROICA Funding Number: W81XWH 21 PCRP HEROICA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOD Peer Reviewed Alzheimer’s, Convergence Science Research Award Apply for W81XWH 21 PRARP CSRA Funding Number: W81XWH 21 PRARP CSRA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOD Peer Reviewed Alzheimer’s, Accelerating Diagnostics Research Award Apply for W81XWH 21 PRARP ADRA Funding Number: W81XWH 21 PRARP ADRA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOD Peer Reviewed Alzheimer’s, Research Partnership Award Apply for W81XWH 21 PRARP RPA Funding Number: W81XWH 21 PRARP RPA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOD Peer Reviewed Alzheimer’s, Innovations in Care and Support Award Apply for W81XWH 21 PRARP INCASA Funding Number: W81XWH 21 PRARP INCASA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOD Peer Reviewed Alzheimer’s, Leveraging Approaches for Innovation in Care and Support Award Apply for W81XWH 21 PRARP LEAP INCASA Funding Number: W81XWH 21 PRARP LEAP INCASA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Racial Equity in STEM Education Apply for PD 21 191Y Funding Number: PD 21 191Y Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $5,000,000 |
| Grand Challenges in Integrative Geospace Sciences: Advancing National Space Weather Expertise and Research toward Societal Resilience Apply for 21 577 Funding Number: 21 577 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $2,500,000 |
| DoD Epilepsy, Research Partnership Award Apply for W81XWH 21 ERP RPA Funding Number: W81XWH 21 ERP RPA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "W81XWH 21 PRORP CTA", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.